AstraZeneca Pharmaceuticals LP D0816L00003 Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

IRB17-106
Cancer, Cancer-Gynecologic
James Hoffman, MD

D'Amour Center for Cancer Care

3350 Main Street
Springfield, MA 01199

This research study is designed to see if olaparib is effective in treating high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer and whether it causes any side effects. A capsule formulation of olaparib (tradename Lynparza™) is approved by both the European Commission (EC), US Food and Drug Administration (FDA) and other countries for the treatment of women with advanced BRCA-mutated ovarian cancer.
Diagnosis of platinum-sensitive epithelial ovarian, fallopian, or primary peritoneal cancer
Laura Sorci
413-794-3188